2020
Treatment of Multiorgan Sarcoidosis With Tofacitinib
Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology 2020, 2: 106-109. PMID: 31916703, PMCID: PMC7011417, DOI: 10.1002/acr2.11112.Peer-Reviewed Original ResearchMultiorgan sarcoidosisTumor necrosis factor α blockadeNecrosis factor α blockadeCutaneous sarcoidosis lesionsEfficacy of tofacitinibIdiopathic inflammatory disorderJanus kinase inhibitorRecalcitrant sarcoidosisΑ-blockadeClinical remissionSarcoidosis lesionsGranulomatous inflammationInflammatory disordersAvid lesionsLesional tissueSarcoidosisJanus kinase-signal transducerSingle patientJAK inhibitorsJAK inhibitionKinase-signal transducerTofacitinibKinase inhibitorsActivator of transcriptionInternal organs
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients